In the new generation of hepatitis C treatment regimens, drugs called nucleotide analogs, or “nucs,” are the golden ticket.
Gilead Sciences’ blockbuster drug Sovaldi, which it acquired in its $11 billion purchase of Pharmasset, is a nuc. Idenix, which agreed to be acquired by Merck Monday for $3.9 billion—more than three-times its closing market value Friday—is developing a nuc. Bristol-Myers bought Inhibitex in 2012 for $2.5 billion for its nuc, only to unwind the program later as safety issues arose.
Help employers find you! Check out all the jobs and post your resume.
